VTYXVentyx Biosciences
About Ventyx Biosciences
Ventyx Biosciences (NASDAQ:VTYX) is a biopharmaceutical entity focused on developing innovative therapies for autoimmune diseases and inflammatory disorders. The company is dedicated to advancing a pipeline of novel small molecule solutions designed to modulate key pathways involved in the immune response. Ventyx Biosciences aims to address unmet medical needs by bringing forth groundbreaking treatments that offer better safety, efficacy, and convenience for patients. With a commitment to scientific excellence and patient care, Ventyx Biosciences continues to seek out opportunities to expand its portfolio and impact lives positively through cutting-edge research and development efforts.
What is VTYX known for?
Snapshot
Public US
Ownership
2018
Year founded
80
Employees
California, United States
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Produtos e/ou serviços de Ventyx Biosciences
- Development of selective TYK2 inhibitors for autoimmune and inflammatory diseases, offering a targeted approach in treating conditions like psoriasis and lupus.
- Creation of a novel therapeutic for inflammatory bowel disease, focusing on a unique molecular target to provide relief for patients with this chronic condition.
- Advancement of an oral small molecule drug targeting S1P1 receptors for the treatment of multiple sclerosis, aiming to provide an improved safety profile over existing therapies.
- Development of therapies targeting the IL-17 pathway, focusing on innovative treatments for dermatological conditions.
- Research into JAK inhibitors for the treatment of rheumatoid arthritis, aiming to offer more effective and less toxic options for patients.
- Exploration of new treatments for alopecia, leveraging cutting-edge science to address hair loss with novel biological pathways.
equipe executiva do Ventyx Biosciences
- Dr. Sheila K. Gujrathi M.D.Executive Chairperson
- Dr. Raju S. Mohan Ph.D.Founder, CEO, President & Director
- Mr. Matthew Richard MooreChief Operating Officer
- Dr. Mark S. Forman M.D., Ph.D.Chief Medical Officer
- Mr. Roy M. Gonzales CPA, M.B.A.Senior VP of Finance and Principal Financial & Accounting Officer
- Dr. John M. Nuss Ph.D.Chief Scientific Officer
- Ms. Snehal Naik Ph.D.Senior Vice President of Clinical Development
- Ms. Kathy Ogilvie Ph.D.Senior Vice President of Translational & Nonclinical Research
- Ms. Arline NakanishiSenior Vice President of Biometrics